Abecma

FDA Advisers Recommend Carvykti and Abecma for Earlier Use in Cancer Patients

by

Washington, D.C. – Amid concerns of early patient deaths, FDA advisors have given their support to Johnson & Johnson and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma for use in earlier stages of treatment. The panel of experts reviewed data for these CAR-T cell therapies which target cancer cells more effectively. Even … Read more

FDA Warning: Early Deaths Reported in CAR-T Myeloma Trials for J&J and Legend’s Carvykti, Bristol Myers’ Abecma

by

Washington, D.C. – The FDA has raised concerns over early deaths in clinical trials for CAR-T therapies used to treat myeloma, a type of blood cancer. The trials involved Johnson & Johnson and Legend’s Carvykti, as well as Bristol Myers’ Abecma. The FDA is closely monitoring these trials to ensure patient safety and efficacy of … Read more